/
IMVT
$41.82-$0.78 (-1.83%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$8.8B
207M shares
52-week range
$14.47 – $42.92
96% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change+$34.32
Immunovant, Inc. Common Stock
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
www.immunovant.com- Employees
- 315
- IPO / List date
- Jun 21, 2019
- HQ
- DURHAM, NC
Held by traders on TradeandTell
No one on the platform currently holds IMVT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 192,500 | $4.8M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded IMVT yet.
